|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.11.26 - 00:06
|
Zocdoc Brings AI to Healthcare (Bloomberg)
|
|
|
AI agents are moving into health care, taking on tasks from finding an in-network doctor to booking appointments around a patient's schedule. Zocdoc CEO Oliver Kharraz says traffic to the platform from AI agents has grown nearly 30-fold since July and has been doubling roughly every 10 days since early September. He joins Bloomberg Businessweek Daily to discuss how the company is openings its doors to AI while keeping patient privacy intact. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.26 - 20:18
|
Google′s Gemini Targets Health Care′s Data Problem (Bloomberg)
|
|
|
Google Cloud is launching Gemini for Health Care, an AI platform designed to connect fragmented information across hospitals, insurers and other health systems while reducing administrative work. Aashima Gupta, Global Leader of Healthcare at Google Cloud, discusses how Gemini can connect medical records, clinical guidelines and business systems, and how Google is building privacy, security and HIPAA compliance into the platform. She joins Riley Griffin on "Bloomberg Tech." (Source: Bloomberg)...
|
|
|
|
|
10.11.26 - 16:48
|
Linnemann: Pharma-Standortpolitik nicht mit Beitragsgeldern (DPA-AFX)
|
|
|
BERLIN (dpa-AFX) - Bundesgesundheitsminister Carsten Linnemann befürwortet Preisvorteile für Arzneimittelhersteller mit Produktion und Investitionen in Deutschland, aber nicht auf Kosten der gesetzlichen Krankenkassen. "Standortpolitik müssen wir natürlich ......
|
|
|
|
|
|
|
10.11.26 - 14:18
|
Pharma firms′ focus on weight-loss drugs could put insulin supply at risk, experts warn (The Guardian)
|
|
|
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms' attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue reading......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
